Last reviewed · How we verify
NCT06754306
Dynamic Effects of Different Dietary Interventions on Visceral Fat and Biochemical Markers
NA trial testing Balanced diet (100% energy) in Energy Metabolism in 84 participants. Completed in 9 June 2025.
9 June 2025
Quick facts
| Lead sponsor | Shanghai Jiao Tong University School of Medicine |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 84 |
| Start date | 25 August 2024 |
| Primary completion | 9 June 2025 |
| Estimated completion | 9 June 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Balanced diet (100% energy)
- 16+8 time-restricted eating group (100% energy)
- 16+8 time-restricted eating group (75% energy)
- Alternate-day fasting group (75% energy)
- 5+2 intermittent fasting group (75% energy)
- Low-calorie diet group (75% energy)
- Very low-calorie diet group (45% energy)
Conditions studied
- Energy Metabolism — all drugs for Energy Metabolism →
Sponsor
Shanghai Jiao Tong University School of Medicine
Who can join
Adults 18 to 35, any sex, with Energy Metabolism. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This randomized clinical trial aims to evaluate the dynamic effects of various dietary interventions on visceral fat and biochemical markers among healthy adults. Participants aged 18-35 years with a normal body mass index (BMI 18.5-23.9) will be recruited from the community. Exclusion criteria include metabolic diseases, unstable weight, medication use, or pregnancy. Participants will be randomly assigned to one of seven groups: 1) balanced diet (100% energy), 2) time-restricted eating (16+8, 100% energy), 3) time-restricted eating (16+8, 75% energy), 4) alternate-day fasting (75% energy), 5) 5+2 fasting (75% energy), 6) low-calorie diet (75% energy), and 7) very low-calorie diet (45% energy). The intervention consists of a 1-week baseline phase, a 4-week dietary intervention phase, and a 28-week recovery phase. Primary outcomes include changes in visceral fat area, while secondary outcomes include body composition, cardiovascular health indicators (e.g., blood pressure, cholesterol), inflammation markers, and liver/kidney function. Biological samples (blood, urine, and feces) will be collected at multiple time points to facilitate multi-omics analyses, including proteomics, metabolomics, metagenomics, and DNA methylation. The study aims to compare the short-term effects of different dietary interventions and explore underlying biological mechanisms. Findings will provide evidence for public health policies and dietary guidelines related to weight management and metabolic health.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06754306
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Energy Metabolism
Currently open trials in the same condition.
- NCT07454252 — Retrospective Monocentric Evaluation of Biomarkers Associated With Bone, Muscle and Energy Metabolism · recruiting
- NCT07056504 — Technologies and Systems for Assessing Human Energy Metabolism and Nutritional Rehabilitation · recruiting
- NCT07478211 — Menstrual Cycle Mapping While Using Closed-Loop Insulin Delivery · recruiting
- NCT05736302 — Validating a New Machine-Learned Accelerometer Algorithm Using Doubly Labeled Water · recruiting
- NCT06483542 — Bionenergetic Balance During CVVH · active not recruiting
Other Shanghai Jiao Tong University School of Medicine trials
Trials by the same sponsor.
- NCT07570810 — Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DM · NA · not yet recruiting
- NCT07528079 — Organoid-based Sensitivity-guided Chemotherapy for Advanced / Refractory Pediatric Tumors · NA · enrolling by invitation
- NCT07535710 — Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-ce · Phase 1, PHASE2 · not yet recruiting
- NCT07535762 — Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T · Phase 2 · not yet recruiting
- NCT07350057 — A Preliminary Clinical Study on the Efficacy of Cyclophosphamide and Sirolimus Combined With VIC-1911 in Preventing Graf · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06754306 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Jiao Tong University School of Medicine
- Last refreshed: 28 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06754306.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing